Organization (Industry)
InSightec (Israel)
ClinicalTrials.gov lists InSightec (Israel) as lead sponsor of 84 trials. It has 19 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Xenmen, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers InSightec (Israel): 84 lead-sponsored trials and 1 legal-entity registration.
Disease areas (43)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Parkinson Disease | 18 |
| Essential Tremor | 14 |
| Glioma | 12 |
| Leiomyoma | 11 |
| Pain | 10 |
Showing 5 of 43 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 6 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 8 |
| 2018 | 8 |
| 2017 | 4 |
Showing 10 of 25 years.
Prediction, not a registry value: median of 35 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 56 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Iptilimumab | Brain Neoplasms | Phase 3 | 1 |
| Iptilimumab | Lung Neoplasms | Phase 3 | 1 |
| Iptilimumab | Carcinoma, Non-Small-Cell Lung | Phase 3 | 1 |
| NIVOLUMAB | Brain Neoplasms | Phase 3 | 1 |
| NIVOLUMAB | Carcinoma, Non-Small-Cell Lung | Phase 3 | 1 |
Showing 5 of 19 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 1 |
| ATEZOLIZUMAB | 1 |
| Cemiplimab | 1 |
| PEMBROLIZUMAB | 1 |
| DOXORUBICIN | 2 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=35) | 26% on time (n=35) |
Journals published in (29)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of neurosurgery | 5 |
| The New England journal of medicine | 4 |
| Fertility and sterility | 3 |
| Journal of neurology, neurosurgery, and psychiatry | 3 |
| Movement disorders : official journal of the Movement Disorder Society | 3 |
Showing 5 of 29 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 70 | 25 | 2025-12-16 |
Financing and grant events (2)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-06-17 | Private placement | 150,000,000 | Form d |
| 2020-03-18 | Private placement | 136,413,679 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| INSIGHTEC, LTD. | TIRAT CARMEL Haifa, IL | FDA |
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Focused Ultrasound Foundation | Co sponsors trial with | 3 |
| University System of Maryland | Co sponsors trial with | 2 |
| Nader Sanai | Co sponsors trial with | 1 |
| Ivy Brain Tumor Center | Co sponsors trial with | 1 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (170)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 170 events.
Biomarker capability evidence (62)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CCNG1 | Trial sponsor | Named in trial inclusion criteria |
| EPO | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
| F3 | Trial collaborator | Named in trial inclusion criteria |
| FUS | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 62 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.